NO982329D0 - Kreftvaksine og fremgangsmÕte for fremstilling derav - Google Patents

Kreftvaksine og fremgangsmÕte for fremstilling derav

Info

Publication number
NO982329D0
NO982329D0 NO982329A NO982329A NO982329D0 NO 982329 D0 NO982329 D0 NO 982329D0 NO 982329 A NO982329 A NO 982329A NO 982329 A NO982329 A NO 982329A NO 982329 D0 NO982329 D0 NO 982329D0
Authority
NO
Norway
Prior art keywords
preparation
cancer vaccine
vaccine
cancer
Prior art date
Application number
NO982329A
Other languages
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Tamos Schweighoffer
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO982329D0 publication Critical patent/NO982329D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO982329A 1995-11-23 1998-05-22 Kreftvaksine og fremgangsmÕte for fremstilling derav NO982329D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
PCT/EP1996/005126 WO1997019169A1 (de) 1995-11-23 1996-11-21 Tumorvakzine und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
NO982329D0 true NO982329D0 (no) 1998-05-22

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982329A NO982329D0 (no) 1995-11-23 1998-05-22 Kreftvaksine og fremgangsmÕte for fremstilling derav

Country Status (24)

Country Link
US (1) US20020085997A1 (no)
EP (1) EP0866851A1 (no)
JP (1) JP2000502052A (no)
KR (1) KR19990067653A (no)
CN (1) CN1202931A (no)
AR (1) AR004341A1 (no)
AU (1) AU720131B2 (no)
BG (1) BG62999B1 (no)
BR (1) BR9611466A (no)
CA (1) CA2238176A1 (no)
CO (1) CO4520254A1 (no)
CZ (1) CZ158998A3 (no)
EE (1) EE03778B1 (no)
HU (1) HUP0000318A3 (no)
NO (1) NO982329D0 (no)
NZ (1) NZ322910A (no)
PL (1) PL188537B1 (no)
RO (1) RO115275B1 (no)
RU (1) RU2206329C2 (no)
SK (1) SK66998A3 (no)
TR (1) TR199800912T2 (no)
TW (1) TW514530B (no)
UY (2) UY24367A1 (no)
WO (1) WO1997019169A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) † 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
JP2001522226A (ja) * 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
DK0904786T3 (da) * 1997-08-22 2005-03-21 Science Park Raf S P A Tumorvaccination under anvendelse af autologe eller HLA-relaterede antigenpræsenterende celler (APC) transduceret med et tumorantigen og et fremmed antigen, som kan fremkalde en immunreaktion
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
WO2003025569A1 (fr) * 2001-09-18 2003-03-27 Kyogo Itoh Procede de detection de l'immunite cellulaire et son application sur des medicaments
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US7579452B2 (en) * 2003-08-25 2009-08-25 Oncomune, Llc Cancer vaccine based on brother of regulator of imprinted sites molecule
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
DE602005005196T2 (de) * 2005-09-05 2008-06-26 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2017159686A1 (ja) 2016-03-15 2017-09-21 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CN114072516A (zh) 2019-05-30 2022-02-18 磨石生物公司 经修饰的腺病毒
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
CA3211645A1 (en) * 2021-03-12 2022-09-15 Erika VON EUW Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0569678A3 (en) * 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.

Also Published As

Publication number Publication date
UY24430A1 (es) 1997-07-01
AU7694796A (en) 1997-06-11
CN1202931A (zh) 1998-12-23
UY24367A1 (es) 2000-10-31
EP0866851A1 (de) 1998-09-30
RO115275B1 (ro) 1999-12-30
EE9800161A (et) 1998-12-15
JP2000502052A (ja) 2000-02-22
EE03778B1 (et) 2002-06-17
KR19990067653A (ko) 1999-08-25
BG102439A (en) 1999-01-29
NZ322910A (en) 2000-05-26
TW514530B (en) 2002-12-21
HUP0000318A3 (en) 2002-02-28
BR9611466A (pt) 1999-05-18
TR199800912T2 (xx) 1998-08-21
BG62999B1 (bg) 2001-01-31
AU720131B2 (en) 2000-05-25
HUP0000318A2 (hu) 2000-06-28
US20020085997A1 (en) 2002-07-04
PL188537B1 (pl) 2005-02-28
SK66998A3 (en) 1998-12-02
AR004341A1 (es) 1998-11-04
CO4520254A1 (es) 1997-10-15
CA2238176A1 (en) 1997-05-29
WO1997019169A1 (de) 1997-05-29
CZ158998A3 (cs) 1999-06-16
RU2206329C2 (ru) 2003-06-20
PL326756A1 (en) 1998-10-26

Similar Documents

Publication Publication Date Title
NO982329D0 (no) Kreftvaksine og fremgangsmÕte for fremstilling derav
IS4879A (is) Efnablöndur dreifanlegra stórsameinda og aðferðirtil gerðar þeirra og notkunar
NO20015888D0 (no) Implanterbare gelpreparater og fremgangsmåte for fremstilling
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
NO980440D0 (no) Infrarödt strålingselement og fremgangsmåte for fremstilling derav
NO970532D0 (no) System og metode for blodbehandling
NO974572D0 (no) Cyklodextrin-forbindelser, fremgangsmåter for fremstilling og anvendelse derav
NO953684D0 (no) Fremgangsmåte for fremstilling av kreftvaksiner
IS4940A (is) Erýtrómýsín og aðferð við að framleiða þau
NO973365D0 (no) Fremgangsmåte for baking og tilhörende anordning
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
NO981108L (no) Freseapparat og fremgangsmÕte ved fresing
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
KR970000228A (ko) S-에토돌락의 경구용 제제
NO972477D0 (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
NO980257D0 (no) Forankringsinnretning, og fremgangsmåte ved forankring
DK0702344T3 (da) Etiketkontinuum og fremgangsmåde til fremstilling deraf
DK0784986T3 (da) Kunstigt hår til implantation og fremgangsmåde tilfremstilling heraf
DK0635004T3 (da) 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
NO995034D0 (no) Tannimplantatsystem og fremgangsmåte for dettes fremstilling
PL323177A1 (en) Azacycloalcane derivatives, method of obtaining them and their application for therapeutic purposes
NO932282L (no) Oljeaktig preparat og fremgangsmaate for fremstilling av dette
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
DK0512547T3 (da) Smertekontrollerende præparat og fremgangsmåde til fremstilling deraf
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer